[Federal Register Volume 84, Number 63 (Tuesday, April 2, 2019)]
[Notices]
[Page 12626]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06389]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-0218]
Pulmonary-Allergy Drugs Advisory Committee; Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Pulmonary-Allergy Drugs Advisory Committee
scheduled for March 27, 2019, has been cancelled. This meeting was
announced in the Federal Register of January 31, 2019. This meeting has
been cancelled due to new information regarding the application. The
Agency intends to continue evaluating the application and, as needed,
will announce future meeting dates in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Cindy Chee, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax:
301-847-8533, email: [email protected], or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), and follow the prompts to the desired center or product area.
Please call the Information Line for up-to-date information on this
meeting, which was announced in the Federal Register of January 31,
2019 (84 FR 748).
Dated: March 28, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
[FR Doc. 2019-06389 Filed 4-1-19; 8:45 am]
BILLING CODE 4164-01-P